CN114948801A - Protective composition with relieving effect and preparation method thereof - Google Patents
Protective composition with relieving effect and preparation method thereof Download PDFInfo
- Publication number
- CN114948801A CN114948801A CN202210671606.2A CN202210671606A CN114948801A CN 114948801 A CN114948801 A CN 114948801A CN 202210671606 A CN202210671606 A CN 202210671606A CN 114948801 A CN114948801 A CN 114948801A
- Authority
- CN
- China
- Prior art keywords
- emollient
- oil
- phase material
- polarity
- protective composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 230000001681 protective effect Effects 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000000694 effects Effects 0.000 title abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 46
- 239000003974 emollient agent Substances 0.000 claims abstract description 44
- 239000003921 oil Substances 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000000341 volatile oil Substances 0.000 claims abstract description 30
- 239000000077 insect repellent Substances 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 16
- 239000003906 humectant Substances 0.000 claims abstract description 15
- 150000001335 aliphatic alkanes Chemical class 0.000 claims abstract description 14
- 150000002148 esters Chemical class 0.000 claims abstract description 14
- UODXCYZDMHPIJE-UHFFFAOYSA-N menthanol Chemical compound CC1CCC(C(C)(C)O)CC1 UODXCYZDMHPIJE-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000012071 phase Substances 0.000 claims description 42
- 235000019198 oils Nutrition 0.000 claims description 37
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 19
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 238000001816 cooling Methods 0.000 claims description 15
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 9
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 9
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000001509 sodium citrate Substances 0.000 claims description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 9
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 8
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 8
- LEEDMQGKBNGPDN-UHFFFAOYSA-N 2-methylnonadecane Chemical compound CCCCCCCCCCCCCCCCCC(C)C LEEDMQGKBNGPDN-UHFFFAOYSA-N 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000005871 repellent Substances 0.000 claims description 6
- 230000002940 repellent Effects 0.000 claims description 6
- 235000019717 geranium oil Nutrition 0.000 claims description 5
- 239000010648 geranium oil Substances 0.000 claims description 5
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 4
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 4
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 4
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 4
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 4
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 4
- LCVHZNSIAYNAGX-UHFFFAOYSA-N 2-ethylhexyl 3,5,5-trimethylhexanoate Chemical compound CCCCC(CC)COC(=O)CC(C)CC(C)(C)C LCVHZNSIAYNAGX-UHFFFAOYSA-N 0.000 claims description 3
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 claims description 3
- BRORPGSJXSLXKN-UHFFFAOYSA-N 6-methylheptyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCOC(=O)CC(C)CC(C)(C)C BRORPGSJXSLXKN-UHFFFAOYSA-N 0.000 claims description 3
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 claims description 3
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 3
- 229940100549 ethylhexyl isononanoate Drugs 0.000 claims description 3
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 claims description 3
- 229940078546 isoeicosane Drugs 0.000 claims description 3
- 239000013521 mastic Substances 0.000 claims description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 3
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 claims description 2
- 240000008632 Cota tinctoria Species 0.000 claims description 2
- 235000020221 chamomile extract Nutrition 0.000 claims description 2
- 229940119217 chamomile extract Drugs 0.000 claims description 2
- 239000000294 eucalyptus globulus labille leaf/twig oil Substances 0.000 claims description 2
- 239000001734 eugenia caryophyllata l. bud oleoresin Substances 0.000 claims description 2
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 239000004909 Moisturizer Substances 0.000 claims 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 51
- 241000255925 Diptera Species 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000013642 negative control Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 6
- 206010040914 Skin reaction Diseases 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000001846 repelling effect Effects 0.000 description 6
- 230000035483 skin reaction Effects 0.000 description 6
- 231100000430 skin reaction Toxicity 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000001342 boswellia carteri birdw. oil Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 241000256173 Aedes albopictus Species 0.000 description 2
- 241000717739 Boswellia sacra Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 244000166124 Eucalyptus globulus Species 0.000 description 2
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 239000004863 Frankincense Substances 0.000 description 2
- 244000178870 Lavandula angustifolia Species 0.000 description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 2
- 244000270673 Pelargonium graveolens Species 0.000 description 2
- 235000017927 Pelargonium graveolens Nutrition 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000009993 protective function Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- FAMJUFMHYAFYNU-UHFFFAOYSA-N 1-methyl-4-(propan-2-yl)cyclohex-1-ene Chemical compound CC(C)C1CCC(C)=CC1 FAMJUFMHYAFYNU-UHFFFAOYSA-N 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 244000165852 Eucalyptus citriodora Species 0.000 description 1
- 235000004722 Eucalyptus citriodora Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- JCMWSVNNSPUNER-UHFFFAOYSA-N N,O-dimethyltyramine Chemical compound CNCCC1=CC=C(OC)C=C1 JCMWSVNNSPUNER-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 240000004277 Pelargonium radens Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000032669 eclosion Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108091005708 gustatory receptors Proteins 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- -1 menthane diol Chemical class 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001298 pelargonium graveolens oil Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000013215 result calculation Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Pest Control & Pesticides (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a protective composition with a relieving effect and a preparation method thereof, wherein the protective composition comprises the following components in parts by weight: 10-99.93% of water phase material components and 0.07-90% of oil phase material components; the oil phase material body components comprise: 0.01-30% of menthanol, 0.01-5% of anti-inflammatory essential oil, 0.01-5% of mosquito repellent essential oil, 0.01-5% of high-polarity emollient, 0.01-10% of high-polarity alcohol humectant, 0.01-30% of isomerized ester emollient and 0.01-5% of isomerized alkane emollient. The protective composition provided by the invention is mild in component and has the advantages of mosquito repellent protection and relieving effects.
Description
Technical Field
The invention relates to the technical field of daily chemicals, in particular to a protective composition with a relieving effect and a preparation method thereof.
Background
Mosquitoes can spread various diseases such as malaria, dengue fever and the like, the mosquitoes breed in the season of full emergence, and the frequency of insect-bite dermatitis on a human body is obviously increased; the skin at the position of the mosquito bite often has the symptoms of papules, edematous erythema and the like, and is accompanied by itching in different degrees, thereby bringing great trouble to people.
For a long time, the components of the pesticide occupy the main position in the field of protective products due to good mosquito repelling and killing effect and long effective time, but have the following defects: the mosquito can generate drug resistance and environmental pollution after long-term use, and can generate great toxic and side effects on human bodies.
The prior art also provides a protective product without pesticide ingredients, but the ingredients often contain allergens such as essence, preservatives and the like, so that the protective product has irritation risks to human bodies and skins; in addition, part of the products have high ethanol content, strong irritation to skin, easy ignition during use and potential safety hazard.
Therefore, with the improvement of the living standard of the materials of people, daily chemical products play an increasingly important role in the life of people and bear the efficacy appeal of people in all aspects; the existing protective products sold in the market have single function, can only play a mosquito repelling protective function or a relieving function, and simultaneously, the component mildness cannot meet the requirements of consumers.
Disclosure of Invention
The invention aims to provide a protective composition with a relieving effect and a preparation method thereof, and aims to solve the problems of single function and insufficient mildness of the conventional protective product.
The embodiment of the invention provides a protective composition, which comprises the following components in percentage by weight: 10-99.93% of water phase material component and 0.07-90% of oil phase material component; the oil phase material components include: 0.01-30% of menthanol, 0.01-5% of anti-inflammatory essential oil, 0.01-5% of mosquito repellent essential oil, 0.01-5% of high-polarity emollient, 0.01-10% of high-polarity alcohol humectant, 0.01-30% of isomerized ester emollient and 0.01-5% of isomerized alkane emollient.
Further, the aqueous phase material body components include: 0.01-0.1% of EDTA disodium, 0.1-1.0% of 1, 2-hexanediol, 0.1-1.0% of p-hydroxyacetophenone, 0.5-5% of butanediol, 0.01-1.0% of sodium chloride, 0.01-0.5% of citric acid, 0.01-0.5% of sodium citrate and 0.9-99.19% of water.
Further, the proportion of EDTA disodium in the water phase material components is 0.02-0.04%, the proportion of 1, 2-hexanediol is 0.2-0.6%, the proportion of p-hydroxyacetophenone is 0.2-0.6%, the proportion of butanediol is 1-3%, the proportion of sodium chloride is 0.1-0.5%, the proportion of citric acid is 0.02-0.2%, the proportion of sodium citrate is 0.02-0.2% and the proportion of water is 40.86-72.04%.
Furthermore, the oil phase body components comprise 5-10% of menthandiol, 0.2-1.5% of anti-inflammatory essential oil, 0.2-1.5% of mosquito repellent essential oil, 2-4% of high-polarity emollient, 2-8% of high-polarity alcohol humectant, 15-25% of isomerized ester emollient and 2-4% of isomerized alkane emollient.
Further, the anti-inflammatory essential oil is one of frankincense oil, golden chamomile extract and clove leaf oil;
the mosquito-repellent essential oil is one of geranium oil, lavender oil and eucalyptus globulus leaf oil;
the high-polarity emollient is one of octyl dodecanol, caprylic/capric triglyceride and C12-14 alcohol benzoate;
the high-polarity alcohol humectant is one of dipropylene glycol, ethoxy diglycol and diethoxy diglycol;
the isomerized ester emollient is one of isononyl isononanoate, isodecyl isononanoate and ethylhexyl isononanoate;
the isomerized alkane emollient is one of isohexadecane, isododecane and isoeicosane.
The embodiment of the invention also provides a preparation method of the protective composition, which comprises the following steps:
the preparation process of the water phase material body comprises the following steps:
adding a preset amount of water into a water kettle, stirring and heating to a first preset temperature;
adding EDTA disodium, 1, 2-hexanediol, p-hydroxyacetophenone and butanediol, stirring for dissolving, and keeping the temperature for a preset time;
cooling to a second preset temperature, adding the sodium chloride, the citric acid and the sodium citrate dissolved by using the residual water, and uniformly stirring;
cooling to a temperature below a third preset temperature and filtering to obtain the water phase material body;
the preparation process of the oil phase material body comprises the following steps:
adding menthanol, a high-polarity emollient and a high-polarity alcohol humectant into an oil pan, heating to a fourth preset temperature, and stirring until the menthanol, the high-polarity emollient and the high-polarity alcohol humectant are dissolved;
adding an isomerized ester emollient and an isomerized alkane emollient, stirring and cooling;
cooling to a second preset temperature, adding the anti-inflammatory essential oil and the mosquito-repellent essential oil, and uniformly stirring;
cooling to a temperature below a third preset temperature and filtering to obtain the oil phase material body;
and filling the water phase material body firstly, and then filling the oil phase material body to obtain the protective composition.
The embodiment of the invention provides a protective composition with a relieving effect and a preparation method thereof, wherein the protective composition comprises the following components in parts by weight: 10-99.93% of water phase material component and 0.07-90% of oil phase material component; the oil phase material components include: 0.01-30% of menthanol, 0.01-5% of anti-inflammatory essential oil, 0.01-5% of mosquito repellent essential oil, 0.01-5% of high-polarity emollient, 0.01-10% of high-polarity alcohol humectant, 0.01-30% of isomerized ester emollient and 0.01-5% of isomerized alkane emollient. The protective composition provided by the embodiment of the invention is mild in component and has the advantages of mosquito repellent protection and relieving effects.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without creative efforts.
Fig. 1 is a schematic flow chart of a method for preparing a repellent composition according to an embodiment of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
It will be understood that the terms "comprises" and/or "comprising," when used in this specification and the appended claims, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.
It is also to be understood that the terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in the specification of the present invention and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
It should be further understood that the term "and/or" as used in this specification and the appended claims refers to and includes any and all possible combinations of one or more of the associated listed items.
The embodiment of the invention provides a protective composition, which comprises a water phase material body component and an oil phase material body component;
the water phase material comprises the following components in percentage by weight: 0.01 to 0.1 percent of EDTA disodium, 0.1 to 1.0 percent of 1, 2-hexanediol, 0.1 to 1.0 percent of p-hydroxyacetophenone, 0.5 to 5 percent of butanediol, 0.01 to 1.0 percent of sodium chloride, 0.01 to 0.5 percent of citric acid, 0.01 to 0.5 percent of sodium citrate and 0.9 to 99.19 percent of water;
the oil phase material body comprises the following components in percentage by weight: 0.01-30% of menthanol, 0.01-5% of anti-inflammatory essential oil, 0.01-5% of mosquito repellent essential oil, 0.01-5% of high-polarity emollient, 0.01-10% of high-polarity alcohol humectant, 0.01-30% of isomerized ester emollient and 0.01-5% of isomerized alkane emollient.
Based on the active ingredients (menthanol, anti-inflammatory essential oil and mosquito-repellent essential oil) in the embodiment, the mosquito-repellent and soothing synergistic effect is achieved.
In one embodiment, the specific proportions of the aqueous phase body components are preferably: 0.02-0.04% of EDTA disodium, 0.2-0.6% of 1, 2-hexanediol, 0.2-0.6% of p-hydroxyacetophenone, 1-3% of butanediol, 0.1-0.5% of sodium chloride, 0.02-0.2% of citric acid, 0.02-0.2% of sodium citrate and 40.86-72.04% of water.
In one embodiment, the specific proportions of the oil phase body components are preferably: 5-10% of menthanol, 0.2-1.5% of anti-inflammatory essential oil, 0.2-1.5% of mosquito repellent essential oil, 2-4% of high-polarity emollient, 2-8% of high-polarity alcohol humectant, 15-25% of isomerized ester emollient and 2-4% of isomerized alkane emollient.
Wherein:
the anti-inflammatory essential oil can be Olibanum (Boswellia CARTERII) oil, flos Chrysanthemi (Chrysanthemum INDICUM) extract and flos Caryophylli (Eugenia CARYOPHYLLUS) leaf oil, which have anti-inflammatory effect, preferably Olibanum oil;
the mosquito repellent essential oil can be Pelargonium GRAVEOLENS (Pelargonium GRAVEOLENS) oil, Lavandula angustifolia (Lavandula angustifolia) oil, Eucalyptus GLOBULUS (Eucalyptus GLOBULUS) leaf oil, etc. with deodorant and mosquito repellent effects, preferably Pelargonium GRAVEOLENS oil;
the high polarity emollient can be one of octyldodecanol, caprylic/capric triglyceride, and C12-14 alcohol benzoate, with octyldodecanol being preferred in this embodiment;
the high-polarity alcohol humectant may be one of dipropylene glycol, ethoxydiglycol and diethoxydiol, and dipropylene glycol is preferred in this embodiment;
the isomerized ester emollient may be one of isononyl isononanoate, isodecyl isononanoate, and ethylhexyl isononanoate, and is preferably isononyl isononanoate in this embodiment;
the isomerized alkane emollient may be one of isohexadecane, isododecane, isoeicosane, with isohexadecane being preferred in this embodiment.
The mastic oil which is preferred based on this embodiment can activate peroxidase-activated receptors, plays an important role in the healing process of skin injury, has anti-inflammation, and can promote the activation of caspase to prolong cell life. Based on the optimized pelargonium roseum oil, the compound mosquito repellent has an inhibiting effect on fungi, has an antibacterial and acaricidal effect, and can effectively repel mosquitoes by emitted chemical substances. The formulation of menthane diol: the menthandiol is extracted from a natural separation product of the eucalyptus citriodora oil, has the effects of inhibiting the nerve reaction of mosquitoes to an attractant, stimulating taste receptor neurons of the mosquitoes, enabling the aversive taste of the mosquitoes to be bitter, and achieving the effect of repelling the mosquitoes from the source. The extraction method of active ingredients comprising the above mastic oil, geranium oil and menthanol is natural and mild, has high safety and is compatible with skin.
The protective composition prepared on the basis of the water phase material components and the oil phase material components has synergistic effects on mosquito repellent protection, relaxation and the like.
Embodiments of the present invention also provide a method for preparing a protective composition, as shown in fig. 1, comprising:
the preparation process of the water phase material body comprises the following steps:
s101, adding a preset water amount into a water kettle, stirring and heating to a first preset temperature, wherein the first preset temperature can be 80-95 ℃, and more specifically can be 85-90 ℃;
s102, adding EDTA disodium, 1, 2-hexanediol, p-hydroxyacetophenone and butanediol, stirring for dissolving, and keeping the temperature for a preset time, wherein the preset time can be 10-40min, and more specifically can be 30 min;
s103, cooling to a second preset temperature, adding sodium chloride, citric acid and sodium citrate dissolved by using the residual water, and uniformly stirring, wherein the second preset temperature can be 45 ℃;
s104, cooling to a temperature below a third preset temperature, and filtering to obtain a water phase material body, wherein the third preset temperature can be 40 ℃.
The preparation process of the oil phase material body comprises the following steps:
s105, adding menthanol, a high-polarity emollient and a high-polarity alcohol humectant into an oil pan, heating to a fourth preset temperature, and stirring to melt, wherein the fourth preset temperature can be 55-65 ℃, and more specifically can be 60 ℃;
s106, adding an isomerized ester emollient and an isomerized alkane emollient, and stirring and cooling;
s107, cooling to a temperature below a second preset temperature, adding the anti-inflammatory essential oil and the mosquito-repellent essential oil, and uniformly stirring;
s108, cooling to a temperature below a third preset temperature, and filtering to obtain an oil phase material body;
s109, filling the water phase material body firstly, and then filling the oil phase material body to obtain the protective composition.
In this example, the protective composition can be obtained by preparing the composition by the preparation method of steps S101 to S109 based on the above-provided component ratios.
The protective component in the protective composition has pure source, is extracted from natural plants, has no chemical solvent residue, is nontoxic to human body, and can achieve effective and lasting mosquito repellent protective effect.
The protective composition also provides a relieving function on the premise of ensuring the mosquito repelling protective function, and the product has rich functions.
The water phase material body in the protective composition forms a lower water phase, the oil phase material body forms an upper oil phase, a liquid separation technology is formed, and compared with a commercially available liquid product, the prepared protective composition product is more differentiated in appearance and richer in visual and sensory experience.
The efficacy of the repellent composition according to the invention is described in detail below with specific examples and comparative examples shown in table 1:
TABLE 1
Based on the preparation method of the repellent composition provided previously, preparation was performed using the ingredient ratios of examples 1 to 5 and comparative examples 1 to 4 in table 1 to obtain a total of 9 parts of repellent composition corresponding to examples 1 to 5 and comparative examples 1 to 4.
Based on the protective compositions obtained in examples 1 to 5 and comparative examples 1 to 4, tests were carried out using each portion, respectively.
Specifically, testing the mosquito repelling effect:
1. reference basis: GB/T13917.9, hygienic insecticide for pesticide registration indoor efficacy test and evaluation part 9: a repellent.
2. Test materials: adopting a sensitive strain standard test insect bred in a laboratory; i.e., Aedes albopictus (Aedes albopictus), 3-5 days after eclosion.
3. The instrument equipment comprises: the mosquito cage is 400mm long, 300mm wide and 300mm high.
4. The test conditions are as follows: temperature, (26+1) ° c; relative humidity 65% ± 10%.
5. Test subject test: 300 test insects are put into the mosquito cage; the back of the hand of the tester exposes 40mmx40mm skin, and the rest part is closely shielded; the hands are put into a mosquito cage to stay for 2min, close observation shows that the mosquitoes stop falling, and the hands shake the arms to drive the mosquitoes away before the mouth organ pierces the skin, and the number of the mosquitoes is recorded as 1 test insect stop falling; more than 30 test persons and test insects stopped from the past are subjects meeting the test conditions.
6. Repelling test: 4 or more test persons were selected, each of which showed a skin area of 50mmx50mm on the back of each hand, one of which was evenly coated with the protective composition to be tested at a dose of 1.5 μ L/cm2 and exposed 40mmx40mm of the skin, the rest of which was tightly masked, and the other hand was blank. After the corresponding protective composition is coated, the hands are put into a mosquito cage meeting the test conditions for 2min, and whether mosquitoes come and stop falling and blood sucking is observed; testing once every 10min, and judging that the test of the corresponding protective composition is finished as long as one mosquito sucks blood in front; recording the effective protection time (min) of the corresponding protective composition; the contrast test is firstly carried out by the contrast hand every time, the test insects meeting the test conditions can be continuously tested, and the test insects meeting the conditions need to be replaced for testing if the test conditions are not met.
7. And (3) test result calculation: adding the effective protection time of the medicament to 4 subjects and above, taking the average (1 decimal) as the effective protection time (min) of the protective composition corresponding to examples 1-5 and comparative examples 1-4; the calculation results are shown in table 2.
TABLE 2
| Sample (I) | Data of each subject (unit: minute) | Results (unit: minute) |
| Example 1 | 217、206、229、241 | 223.3 |
| Example 2 | 242、254、230、218 | 236 |
| Example 3 | 193、205、217、205 | 205 |
| Example 4 | 266、277、253、265 | 265.3 |
| Example 5 | 212、201、213、219 | 211.3 |
| Comparative example 1 | 193、169、170、181 | 178.3 |
| Comparative example 2 | 14、25、13、25 | 19.3 |
| Comparative example 3 | 49、73、62、50 | 58.5 |
| Comparative example 4 | 2、1、2、2 | 1.8 |
As can be seen from table 2, the protective compositions of examples 1 to 5 can prolong the effective mosquito repellent protection time, i.e., the present invention has the efficacy of mosquito repellent protection, using the protective compositions of examples 1 to 5 as compared to using the protective compositions of comparative examples 1 to 4. In addition, as can be seen from the examples and the comparative examples, the three active components (menthandiol, frankincense oil and geranium oil) in the examples can play a remarkable role in synergistic mosquito repellent protection.
Specifically, the soothing efficacy test:
1. reference basis: cytotoxicity assay MTT method, a test based on the soothing efficacy of C48/80 stimulated mast cells.
2. Test materials: mouse mast cell tumor cells P815, high-sugar DMEM, PBS buffer, MTT thiazole blue, dimethyl sulfoxide DMSO, trypsin and Compound 48/80 (a mixture of N-methyl-P-methoxyphenethylamine and formaldehyde condensation product, abbreviated as C48/80).
3. The instrument equipment comprises: CO 2 2 Incubator, superclean bench, ELIASA and inverted microscope.
4. And (4) testing cytotoxicity.
4.1 cell inoculation: by 1 × 10 4 Cell/well seeding Density cells were seeded into 96-well plates and incubated in an incubator (37 ℃ C., 5% CO) 2 ) And incubated overnight.
4.2 experimental grouping: the experimental set was zero-adjusted, negative control, positive control and sample groups (i.e. the protective compositions corresponding to examples 1-5 and comparative examples 1-4). In the sample set, 5 concentration gradients (0.5%, 1.0%, 2.0%, 5.0%, 10.0% for each example or comparative concentration) were set for each sample, and 3 replicate wells were set for each concentration gradient.
4.3 administration: when the cell plating rate in the 96-well plate reaches 40-60 percent, administration is carried out; adding 200 mu L of culture solution into each hole of the negative control group; adding 200 mu L of culture solution containing 10% DMSO into each well of the positive control group; adding 200 mu L of culture solution containing samples with corresponding concentrations into each well of the sample group; zero-adjusting group is inoculated without cells, and only 200 mu L of cell culture solution is added; after completion of the administration, the 96-well plate was placed in an incubator (37 ℃ C., 5% CO) 2 ) Culturing in medium.
4.4 detection: after 24h of cell incubation culture, the supernatant was discarded, MTT working solution (0.5mg/mL) was added, incubation was performed at 37 ℃ in the dark for 4h, after the incubation was completed, the supernatant was discarded, 150. mu.L of DMSO was added to each well, and the OD was read at 490 nm.
4.5 cell relative viability calculation: calculated according to the formula, the relative cell viability (%) was 100% (sample well OD-zeroed well OD)/(solvent control well OD-zeroed well OD) ].
The test results are shown in Table 3 and in Table 4 for the negative and positive controls.
TABLE 3
TABLE 4
According to the results of the cytotoxicity test, examples 1 to 5 and comparative examples 1 to 4 were not cytotoxic in the concentration range of 2%.
5. And (5) testing the particle removal rate.
5.1 cell inoculation: by 1 × 10 5 Cell/well seeding Density cells were plated onto 24-well plates, incubators (37 ℃, 5% CO) 2 ) And incubated overnight.
5.2, liquid preparation: taking water as a diluent, taking sodium cromoglycate as a positive control test solution: 1 mg/mL; examples 1-5 and comparative examples 1-4 each sample liquid: 1% (by mass).
5.3 administration: when the cell plating rate in the 24-pore plate reaches 40% -50%, performing grouped drug delivery, wherein each group is provided with 3 multiple pores, and each pore is added with a culture medium containing 1mL of sample liquid to be detected; after completion of the administration, the 24-well plate was placed in an incubator (37 ℃ C., 5% CO) 2 ) And culturing for 2 h.
5.4C 48/80 stimulation: after incubating the sample for 2h, discarding the solution; the administration method is C48/80 stimulation administration method shown in Table 5, C48/80 stimulation is carried out for 45min after administration is finished, and the reaction is stopped in ice bath.
TABLE 5
5.5 cell morphology observation: after the culture is finished, scraping the degranulation condition of each group of cells under an inverted microscope, and counting and calculating the degranulation rate of the cells by adopting IPP software; the degranulation statistics are shown in table 6.
TABLE 6
It should be noted that: the invention adopts a t-test method for statistical analysis, and compared with a blank control group, the significance of a negative control group is represented by #, the P value is less than 0.05 and is represented by #, and the P value is less than 0.01 and is represented by #; the significance of the positive control, sample group (i.e. the protective compositions corresponding to examples 1-5 and comparative examples 1-4) compared to the negative control group was similar, with P values < 0.05 indicated by x and P values < 0.01 indicated by x.
Compared with a blank control group, after C48/80 stimulation, a negative control group shows obvious degranulation morphology (P is less than 0.01), and the degranulation cell number of a positive control group is remarkably reduced (P is less than 0.01), which indicates that the C48/80 is adopted to induce the mast cell degranulation model to be successfully established, and the experiment is effective.
The samples of examples 1-5 can reduce the degranulation rate of mast cells compared with the sample of comparative example 4, namely the invention has the efficacy of relieving itching; in addition, as can be seen from the examples and comparative examples, the three active ingredients (i.e., menthene glycol, frankincense oil, geranium oil) in the examples can achieve a remarkable synergistic soothing effect.
Skin occlusion patch test:
1. reference basis: chapter seven of the technical specifications for cosmetic safety (2015), chapter five of the specifications for cosmetic hygiene (2007).
2. Test materials: the area is not more than 50mm 2 And qualified spot test equipment with the depth of about 1 mm.
3. The tested person: meets the inclusion standard of the testee.
4. Testing parts: inside of arm
5. And (3) testing period: 4 days
6. Negative control: blank, no treatment.
7. Testing time points: patch 24 hours, remove patch 0.5 hours, 24 hours, 48 hours.
8. The test scheme is as follows: selecting a qualified test person, selecting a qualified spot tester, putting about 0.020 ml-0.025 ml of a test object (namely the protective composition corresponding to examples 1-5 and comparative examples 1-4) into a small chamber of the spot tester by a closed spot test method, pasting the spot tester on the inner side of the arm of the test person by using a hypoallergenic adhesive tape, and lightly pressing the spot tester with the palm to uniformly paste the spot tester on the skin for 24 hours; the skin reactions were observed at 30min (after disappearance of the indentation), 24h and 48h after removal of the test article patch test according to the skin reaction grading standards for skin-enclosed patch test provided in table 7, and the observation results were recorded.
TABLE 7
In the present example, the evaluation criteria of the results of the skin-closed patch test in the cosmetic hygiene code (2007 edition) were used: the number of people with grade 1 adverse skin reactions is more than 5 in 30 tested persons, or the number of people with grade 2 adverse skin reactions is more than 2 (the number of people with grade 2 reactions in a deodorization product patch test is more than 5), or any 1 example with grade 3 or more than 3 adverse skin reactions occurs, and the tested substance is judged to have adverse skin reactions on the human body. The statistical results of this example are shown in the skin occlusion patch test results in table 8.
TABLE 8
As can be seen from table 8, using the example composition and using the comparative example composition, after 34 subjects removed the patch, 3 observation time points: the reaction time of 0.5h, 24h and 48h is negative, namely the invention is mild to the skin and has no adverse reaction.
Based on the mosquito repellent efficacy test, the soothing efficacy test and the skin-enclosed patch test, the invention proves that the protective composition provided by the invention has synergistic effects in mosquito repellent protection, soothing and the like based on the test results.
The embodiments are described in a progressive manner in the specification, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other. For the system disclosed by the embodiment, the description is relatively simple because the system corresponds to the method disclosed by the embodiment, and the relevant points can be referred to the method part for description. It should be noted that, for those skilled in the art, it is possible to make several improvements and modifications to the present application without departing from the principle of the present application, and such improvements and modifications also fall within the scope of the claims of the present application.
It is further noted that, in the present specification, relational terms such as first and second, and the like are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising an … …" does not exclude the presence of other identical elements in a process, method, article, or apparatus that comprises the element.
Claims (10)
1. A protective composition comprising:
according to the weight ratio, the water phase material comprises 10-99.93% of water phase material and 0.07-90% of oil phase material; the oil phase material body components include: 0.01-30% of menthanol, 0.01-5% of anti-inflammatory essential oil, 0.01-5% of mosquito repellent essential oil, 0.01-5% of high-polarity emollient, 0.01-10% of high-polarity alcohol humectant, 0.01-30% of isomerized ester emollient and 0.01-5% of isomerized alkane emollient.
2. The protective composition of claim 1, wherein the aqueous phase material components comprise: 0.01-0.1% of EDTA disodium, 0.1-1.0% of 1, 2-hexanediol, 0.1-1.0% of p-hydroxyacetophenone, 0.5-5% of butanediol, 0.01-1.0% of sodium chloride, 0.01-0.5% of citric acid, 0.01-0.5% of sodium citrate and 0.9-99.19% of water.
3. The protective composition of claim 2, wherein the aqueous phase of the body components comprises 0.02-0.04% disodium EDTA, 0.2-0.6% 1, 2-hexanediol, 0.2-0.6% p-hydroxyacetophenone, 1-3% butanediol, 0.1-0.5% sodium chloride, 0.02-0.2% citric acid, 0.02-0.2% sodium citrate, and 40.86-72.04% water.
4. The protective composition according to claim 1, wherein the proportion of menthanediol in the oil phase components is 5-10%, the proportion of anti-inflammatory essential oil is 0.2-1.5%, the proportion of mosquito repellent essential oil is 0.2-1.5%, the proportion of high polarity emollient is 2-4%, the proportion of high polarity alcohol moisturizer is 2-8%, the proportion of isomerized ester emollient is 15-25% and the proportion of isomerized alkane emollient is 2-4%.
5. The repellent composition according to claim 1, wherein:
the anti-inflammatory essential oil is one of mastic oil, golden chamomile extract and clove leaf oil;
the mosquito-repellent essential oil is one of geranium oil, lavender oil and eucalyptus globulus leaf oil;
the high-polarity emollient is one of octyl dodecanol, caprylic/capric triglyceride and C12-14 alcohol benzoate;
the high-polarity alcohol humectant is one of dipropylene glycol, ethoxy diglycol and diethoxy diglycol;
the isomerized ester emollient is one of isononyl isononanoate, isodecyl isononanoate and ethylhexyl isononanoate;
the isomerized alkane emollient is one of isohexadecane, isododecane, and isoeicosane.
6. A method of preparing a protective composition, comprising:
the preparation process of the water phase material body comprises the following steps:
adding a preset amount of water into a water kettle, stirring and heating to a first preset temperature;
adding EDTA disodium, 1, 2-hexanediol, p-hydroxyacetophenone and butanediol, stirring for dissolving, and keeping the temperature for a preset time;
cooling to a second preset temperature, adding the sodium chloride, the citric acid and the sodium citrate dissolved by using the residual water, and uniformly stirring;
cooling to a temperature below a third preset temperature and filtering to obtain the water phase material body;
the preparation process of the oil phase material body comprises the following steps:
adding menthanol, a high-polarity emollient and a high-polarity alcohol humectant into an oil kettle, heating to a fourth preset temperature, and stirring until the menthanol, the high-polarity emollient and the high-polarity alcohol humectant are dissolved;
adding an isomerized ester emollient and an isomerized alkane emollient, stirring and cooling;
cooling to a second preset temperature, adding the anti-inflammatory essential oil and the mosquito-repellent essential oil, and uniformly stirring;
cooling to a temperature below a third preset temperature and filtering to obtain the oil phase material body;
and filling the water phase material body firstly, and then filling the oil phase material body to obtain the protective composition.
7. The method of claim 6, wherein the first predetermined temperature is 80-95 ℃.
8. The method of claim 6, wherein the second predetermined temperature is 45 ℃.
9. The method of claim 6, wherein the third predetermined temperature is 40 ℃.
10. The method of claim 6, wherein the fourth predetermined temperature is 55-65 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210671606.2A CN114948801B (en) | 2022-06-14 | 2022-06-14 | Protective composition with relieving effect and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210671606.2A CN114948801B (en) | 2022-06-14 | 2022-06-14 | Protective composition with relieving effect and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114948801A true CN114948801A (en) | 2022-08-30 |
| CN114948801B CN114948801B (en) | 2024-04-30 |
Family
ID=82964342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210671606.2A Active CN114948801B (en) | 2022-06-14 | 2022-06-14 | Protective composition with relieving effect and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114948801B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109589298A (en) * | 2019-01-21 | 2019-04-09 | 水母娘娘海洋生物科技有限公司 | A kind of artemia eggs ghost dispersion liquid and its preparation process and application |
| CN112972689A (en) * | 2020-03-21 | 2021-06-18 | 黄泳华 | Anti-acne composition containing antibiotics and alcohol compounds or vegetable oil |
-
2022
- 2022-06-14 CN CN202210671606.2A patent/CN114948801B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109589298A (en) * | 2019-01-21 | 2019-04-09 | 水母娘娘海洋生物科技有限公司 | A kind of artemia eggs ghost dispersion liquid and its preparation process and application |
| CN112972689A (en) * | 2020-03-21 | 2021-06-18 | 黄泳华 | Anti-acne composition containing antibiotics and alcohol compounds or vegetable oil |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114948801B (en) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107349170B (en) | Folium artemisiae argyi mosquito-repelling itching-relieving floral water and preparation method thereof | |
| CN102366389B (en) | Preparation method for compound mosquito repelling and itching relieving floral water | |
| CN111773140B (en) | Plant essential oil composition and application thereof | |
| CN107996622B (en) | Mosquito repellent containing plant essential oil | |
| WO2018137500A1 (en) | Plant composition, preparation method and application thereof | |
| LINDSAY et al. | Thanaka (Limonia acidissima) and deet (di‐methyl benzamide) mixture as a mosquito repellent for use by Karen women | |
| CN111135209A (en) | Artemisia apiacea spray with effects of preventing malaria, repelling mosquitoes, relieving itching and repairing and preparation method thereof | |
| CN110637839A (en) | Jasmine flower mosquito repellent with nerve calming and sleep aiding effects and preparation method thereof | |
| EP2081428B1 (en) | Antipediculosis composition having a lice-suffocating activity | |
| US11375721B1 (en) | Mosquito repellent composition, preparation method and application thereof | |
| CN112807259B (en) | Safe and nontoxic mosquito-repellent composition and preparation method and application thereof | |
| CN106726871A (en) | Sweet wormwood mosquito-expelling and antipruritic floral water and preparation method thereof | |
| CN102441037A (en) | Mosquito-repelling and itching-relieving cream | |
| CN114948801A (en) | Protective composition with relieving effect and preparation method thereof | |
| CN112219844B (en) | Botanical mosquito repellent and preparation method thereof | |
| CN112494388A (en) | Nonalcoholic spray for repelling mosquitoes and relieving itching and preparation method thereof | |
| Uppala et al. | Formulation and Evaluation of Mosquito Repellent Activity of Polyherbal Formulations of Extraction of Annona squamosa, Azadirachta indica, Eucalyptus alba, Citrus aurantium and Rosa indica and their phytochemical analysis | |
| Yabansabra et al. | The Effectiveness of Zodia Leaves (Evodia Suaveolens Scheff) Oil as Aedes aegypti L Mosquito Repellent in Papua | |
| CN111631963A (en) | Oil-control, dandruff-removing, moisture-preserving and itching-relieving plant mite-removing and skin-cleaning shampoo and preparation process thereof | |
| CN111150688A (en) | Mosquito-repellent prickly heat-removing spray and preparation method thereof | |
| CN110354048A (en) | A kind of natural plant active composition and the preparation method and application thereof | |
| CN112618438B (en) | Mosquito repelling composition suitable for children and preparation method and application thereof | |
| CN114532365B (en) | Composition for preventing and controlling Dictyophora rubrovalvata springtails and application thereof | |
| CN111728895A (en) | Plant essential oil emulsion for repelling mosquitoes, moistening skin and tendering skin and preparation method thereof | |
| CN112545925B (en) | Mosquito-repellent spray composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |